|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLIT2 |
Gene summary for SLIT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLIT2 | Gene ID | 9353 |
| Gene name | slit guidance ligand 2 | |
| Gene Alias | SLIL3 | |
| Cytomap | 4p15.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O94813 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9353 | SLIT2 | AEH-subject1 | Human | Endometrium | AEH | 6.24e-09 | 3.44e-01 | -0.3059 |
| 9353 | SLIT2 | AEH-subject2 | Human | Endometrium | AEH | 6.33e-04 | 3.41e-01 | -0.2525 |
| 9353 | SLIT2 | AEH-subject3 | Human | Endometrium | AEH | 2.92e-03 | 2.63e-01 | -0.2576 |
| 9353 | SLIT2 | AEH-subject4 | Human | Endometrium | AEH | 3.11e-08 | 4.72e-01 | -0.2657 |
| 9353 | SLIT2 | EEC-subject1 | Human | Endometrium | EEC | 8.84e-12 | 4.85e-01 | -0.2682 |
| 9353 | SLIT2 | EEC-subject2 | Human | Endometrium | EEC | 3.93e-54 | 1.10e+00 | -0.2607 |
| 9353 | SLIT2 | EEC-subject5 | Human | Endometrium | EEC | 2.56e-10 | 4.50e-01 | -0.249 |
| 9353 | SLIT2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 7.52e-21 | 7.40e-01 | -0.1934 |
| 9353 | SLIT2 | TD9 | Human | Lung | IAC | 1.60e-04 | 1.02e+00 | 0.088 |
| 9353 | SLIT2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.29e-03 | 5.78e-01 | 0.3371 |
| 9353 | SLIT2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.12e-02 | 5.15e-01 | 0.343 |
| 9353 | SLIT2 | RNA-P17T-P17T-6 | Human | Lung | IAC | 4.45e-02 | 5.48e-01 | 0.3385 |
| 9353 | SLIT2 | RNA-P17T-P17T-8 | Human | Lung | IAC | 7.05e-06 | 6.53e-01 | 0.3329 |
| 9353 | SLIT2 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.89e-06 | 3.99e-01 | -0.2116 |
| 9353 | SLIT2 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.55e-03 | 3.88e-01 | -0.2119 |
| 9353 | SLIT2 | male-WTA | Human | Thyroid | PTC | 1.58e-25 | 3.00e-01 | 0.1037 |
| 9353 | SLIT2 | PTC01 | Human | Thyroid | PTC | 3.90e-06 | 1.75e-01 | 0.1899 |
| 9353 | SLIT2 | PTC04 | Human | Thyroid | PTC | 2.66e-06 | 6.46e-02 | 0.1927 |
| 9353 | SLIT2 | PTC05 | Human | Thyroid | PTC | 8.82e-03 | 2.74e-01 | 0.2065 |
| 9353 | SLIT2 | PTC06 | Human | Thyroid | PTC | 3.32e-19 | 6.12e-01 | 0.2057 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003210324 | Thyroid | ATC | positive regulation of response to external stimulus | 178/6293 | 427/18723 | 2.61e-04 | 1.67e-03 | 178 |
| GO:000165721 | Thyroid | ATC | ureteric bud development | 47/6293 | 91/18723 | 2.85e-04 | 1.82e-03 | 47 |
| GO:006075912 | Thyroid | ATC | regulation of response to cytokine stimulus | 76/6293 | 162/18723 | 2.92e-04 | 1.85e-03 | 76 |
| GO:000182321 | Thyroid | ATC | mesonephros development | 49/6293 | 96/18723 | 3.08e-04 | 1.94e-03 | 49 |
| GO:000195912 | Thyroid | ATC | regulation of cytokine-mediated signaling pathway | 71/6293 | 150/18723 | 3.28e-04 | 2.04e-03 | 71 |
| GO:0051494110 | Thyroid | ATC | negative regulation of cytoskeleton organization | 76/6293 | 163/18723 | 3.68e-04 | 2.27e-03 | 76 |
| GO:00487545 | Thyroid | ATC | branching morphogenesis of an epithelial tube | 71/6293 | 151/18723 | 4.18e-04 | 2.50e-03 | 71 |
| GO:000317912 | Thyroid | ATC | heart valve morphogenesis | 31/6293 | 55/18723 | 4.33e-04 | 2.59e-03 | 31 |
| GO:00509206 | Thyroid | ATC | regulation of chemotaxis | 99/6293 | 223/18723 | 4.91e-04 | 2.86e-03 | 99 |
| GO:001481221 | Thyroid | ATC | muscle cell migration | 54/6293 | 110/18723 | 5.47e-04 | 3.16e-03 | 54 |
| GO:001059431 | Thyroid | ATC | regulation of endothelial cell migration | 102/6293 | 232/18723 | 6.17e-04 | 3.51e-03 | 102 |
| GO:005105812 | Thyroid | ATC | negative regulation of small GTPase mediated signal transduction | 31/6293 | 56/18723 | 6.60e-04 | 3.74e-03 | 31 |
| GO:190274318 | Thyroid | ATC | regulation of lamellipodium organization | 30/6293 | 54/18723 | 7.41e-04 | 4.14e-03 | 30 |
| GO:002198722 | Thyroid | ATC | cerebral cortex development | 55/6293 | 114/18723 | 8.32e-04 | 4.57e-03 | 55 |
| GO:001490914 | Thyroid | ATC | smooth muscle cell migration | 48/6293 | 97/18723 | 8.66e-04 | 4.71e-03 | 48 |
| GO:000328121 | Thyroid | ATC | ventricular septum development | 37/6293 | 71/18723 | 9.80e-04 | 5.21e-03 | 37 |
| GO:000323111 | Thyroid | ATC | cardiac ventricle development | 58/6293 | 123/18723 | 1.23e-03 | 6.46e-03 | 58 |
| GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
| GO:003003216 | Thyroid | ATC | lamellipodium assembly | 37/6293 | 72/18723 | 1.37e-03 | 7.12e-03 | 37 |
| GO:000320612 | Thyroid | ATC | cardiac chamber morphogenesis | 57/6293 | 121/18723 | 1.39e-03 | 7.20e-03 | 57 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0436010 | Endometrium | AEH | Axon guidance | 39/1197 | 182/8465 | 4.47e-03 | 2.46e-02 | 1.80e-02 | 39 |
| hsa0436013 | Endometrium | AEH | Axon guidance | 39/1197 | 182/8465 | 4.47e-03 | 2.46e-02 | 1.80e-02 | 39 |
| hsa0436022 | Endometrium | EEC | Axon guidance | 39/1237 | 182/8465 | 7.78e-03 | 3.66e-02 | 2.73e-02 | 39 |
| hsa0436032 | Endometrium | EEC | Axon guidance | 39/1237 | 182/8465 | 7.78e-03 | 3.66e-02 | 2.73e-02 | 39 |
| hsa043608 | Lung | IAC | Axon guidance | 34/1053 | 182/8465 | 9.31e-03 | 3.62e-02 | 2.41e-02 | 34 |
| hsa0436011 | Lung | IAC | Axon guidance | 34/1053 | 182/8465 | 9.31e-03 | 3.62e-02 | 2.41e-02 | 34 |
| hsa0436021 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
| hsa0436031 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLIT2 | SNV | Missense_Mutation | rs763158714 | c.1507N>T | p.Asp503Tyr | p.D503Y | O94813 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLIT2 | SNV | Missense_Mutation | novel | c.1115T>G | p.Phe372Cys | p.F372C | O94813 | protein_coding | tolerated(0.14) | possibly_damaging(0.763) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLIT2 | SNV | Missense_Mutation | c.4003N>T | p.Pro1335Ser | p.P1335S | O94813 | protein_coding | tolerated(0.39) | benign(0.23) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLIT2 | SNV | Missense_Mutation | novel | c.3353T>C | p.Val1118Ala | p.V1118A | O94813 | protein_coding | tolerated(0.34) | benign(0.009) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLIT2 | SNV | Missense_Mutation | rs749148075 | c.566N>T | p.Arg189Ile | p.R189I | O94813 | protein_coding | tolerated(0.39) | benign(0.216) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLIT2 | SNV | Missense_Mutation | rs767628989 | c.673N>T | p.Arg225Cys | p.R225C | O94813 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| SLIT2 | SNV | Missense_Mutation | c.1112N>C | p.Leu371Pro | p.L371P | O94813 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| SLIT2 | SNV | Missense_Mutation | c.1859G>T | p.Cys620Phe | p.C620F | O94813 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-E9-A24A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SLIT2 | SNV | Missense_Mutation | c.2668N>C | p.Gly890Arg | p.G890R | O94813 | protein_coding | tolerated(0.38) | benign(0.021) | TCGA-EW-A1IX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD | |
| SLIT2 | SNV | Missense_Mutation | rs752006737 | c.3412N>A | p.Val1138Ile | p.V1138I | O94813 | protein_coding | tolerated(0.25) | benign(0.014) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |